Schneider, Constanze <br/><br/>
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.  [electronic resource] 

 -  Nature medicine  Feb 2017 
 - 250-255 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1546-170X 
<br/><br/><label>Standard No.: </label>10.1038/nm.4255  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Antimetabolites, Antineoplastic--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Cytarabine--administration & dosage<br/>Daunorubicin--administration & dosage<br/>Disease Models, Animal<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Immunoblotting<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Monomeric GTP-Binding Proteins--metabolism<br/>Prognosis<br/>Retrospective Studies<br/>SAM Domain and HD Domain-Containing Protein 1<br/>Young Adult